ANIK News & Events

Reports Q1 revenue $29.6M vs. $26.2M last year. Reports total company revenue grew 13%, driven by commercial channel strength and favorable OEM channel order timing. "Our strategic transformation and organizational realignment is yielding results and driving improved profitability and efficiencies throughout the organization," said CEO Steve Griffin.

Reports Q4 revenue $30.6M vs $30.6M last year. "We closed 2025 with a strong fourth quarter, with top-line growth led by our Commercial Channel and company-wide results that included expanded gross margin, and positive operating income and free cash flow," said Steve Griffin, President and Chief Executive Officer of Anika Therapeutics. "Our operating income performance in the fourth quarter and full year underscores the strength of our core OA Pain Management business despite U.S. pricing headwinds in 2025 and establishes a foundation for improved profitability.